Romano Steven J.
SEC insider (Form 3/4/5 filer). CIK 0001639860. Director at Dianthus Therapeutics, Inc. /DE/ (DNTH) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on May 21, 2026. Located in LONDON, X0.
Companies Romano Steven J. has filed insider reports for
- Dianthus Therapeutics, Inc. /DE/ (DNTH): Director
- Silence Therapeutics plc (SLN): Officer, EVP and Chief R&D Officer
Romano Steven J.
CIK: 0001639860
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- May 21, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
AwardDirectStock Option (Right to Buy)
6.1K shares- - Jan 2, 2026SLN
Silence Therapeutics plc
AwardDirectEmployee Share Option (Right to Buy)
300K shares- - May 22, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
AwardDirectStock Option (Right to Buy)
12.5K shares- - Jan 2, 2025SLN
Silence Therapeutics plc
AwardDirectEmployee Share Option (Right to Buy)
285K shares- - Sep 16, 2024DNTH
Dianthus Therapeutics, Inc. /DE/
AwardDirectStock Option (Right to Buy)
22K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 21, 2026 |  DNTH Dianthus Therapeutics, Inc. /DE/ | Award Stock Option (Right to Buy) | 6,090 | - | - | Direct |
| Jan 2, 2026 |  SLN Silence Therapeutics plc | Award Employee Share Option (Right to Buy) | 300,000 | - | - | Direct |
| May 22, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award Stock Option (Right to Buy) | 12,500 | - | - | Direct |
| Jan 2, 2025 | SLN Silence Therapeutics plc | Award Employee Share Option (Right to Buy) | 285,000 | - | - | Direct |
| Sep 16, 2024 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award Stock Option (Right to Buy) | 22,000 | - | - | Direct |
1-5 of 5 transactions